X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (36956) 36956
Book Review (7731) 7731
Publication (1193) 1193
Newsletter (202) 202
Book Chapter (184) 184
Magazine Article (163) 163
Conference Proceeding (90) 90
Newspaper Article (48) 48
Book / eBook (42) 42
Trade Publication Article (18) 18
Dissertation (16) 16
Web Resource (12) 12
Paper (6) 6
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32216) 32216
humans (30632) 30632
heparin - therapeutic use (16388) 16388
female (14310) 14310
male (13396) 13396
anticoagulants - therapeutic use (10803) 10803
heparin (9774) 9774
middle aged (9259) 9259
adult (7770) 7770
aged (7558) 7558
abridged index medicus (6336) 6336
animals (5454) 5454
heparin, low-molecular-weight - therapeutic use (4876) 4876
molecular-weight heparin (4812) 4812
hematology (4651) 4651
anticoagulants (4606) 4606
peripheral vascular disease (4123) 4123
heparin - administration & dosage (3925) 3925
treatment outcome (3831) 3831
risk factors (3717) 3717
heparin - adverse effects (3715) 3715
fibrinolytic agents - therapeutic use (3680) 3680
thrombosis (3631) 3631
anticoagulants - adverse effects (3407) 3407
surgery (3259) 3259
cardiac & cardiovascular systems (3092) 3092
anticoagulants - administration & dosage (2881) 2881
venous thromboembolism (2689) 2689
pregnancy (2683) 2683
unfractionated heparin (2608) 2608
thromboembolism (2567) 2567
time factors (2558) 2558
prevention (2549) 2549
pharmacology & pharmacy (2543) 2543
medicine, general & internal (2480) 2480
deep-vein thrombosis (2284) 2284
aged, 80 and over (2074) 2074
heparin - pharmacology (2067) 2067
prospective studies (2031) 2031
thromboembolism - prevention & control (2009) 2009
retrospective studies (2004) 2004
therapy (1984) 1984
postoperative complications - prevention & control (1929) 1929
warfarin - therapeutic use (1909) 1909
anticoagulation (1897) 1897
adolescent (1881) 1881
aspirin - therapeutic use (1829) 1829
thrombocytopenia - chemically induced (1759) 1759
thrombosis - prevention & control (1680) 1680
care and treatment (1675) 1675
drug therapy, combination (1674) 1674
hemorrhage - chemically induced (1666) 1666
drug therapy (1646) 1646
thrombosis - drug therapy (1620) 1620
platelet aggregation inhibitors - therapeutic use (1618) 1618
thrombolytic therapy (1580) 1580
pulmonary embolism - drug therapy (1570) 1570
enoxaparin (1552) 1552
venous thrombosis - drug therapy (1525) 1525
glycosaminoglycans (1522) 1522
venous thrombosis (1522) 1522
analysis (1518) 1518
myocardial infarction - drug therapy (1511) 1511
risk (1505) 1505
rats (1477) 1477
health aspects (1471) 1471
warfarin (1461) 1461
dose-response relationship, drug (1422) 1422
medicine & public health (1421) 1421
venous thrombosis - prevention & control (1399) 1399
acute disease (1394) 1394
management (1380) 1380
recurrence (1349) 1349
blood coagulation - drug effects (1345) 1345
follow-up studies (1343) 1343
pulmonary embolism (1331) 1331
child (1298) 1298
heparin-induced thrombocytopenia (1288) 1288
cancer (1286) 1286
research (1259) 1259
pulmonary-embolism (1254) 1254
clinical trials as topic (1243) 1243
partial thromboplastin time (1230) 1230
anticoagulants - pharmacology (1220) 1220
pulmonary embolism - prevention & control (1219) 1219
prophylaxis (1218) 1218
blood coagulation tests (1215) 1215
recombinant proteins - therapeutic use (1203) 1203
thrombophlebitis - drug therapy (1190) 1190
aspirin (1167) 1167
heparin, low-molecular-weight - administration & dosage (1162) 1162
mice (1160) 1160
thrombosis - etiology (1150) 1150
diagnosis (1130) 1130
venous thromboembolism - prevention & control (1129) 1129
heparin, low-molecular-weight - adverse effects (1114) 1114
complications (1093) 1093
mortality (1080) 1080
randomized controlled trials as topic (1057) 1057
thrombophlebitis - prevention & control (1054) 1054
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (32) 32
Online Resources - Online (14) 14
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Gerstein Science - Pharmacy (1) 1
Gerstein Science - Theses (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University Archives - Archives (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (31801) 31801
German (1638) 1638
French (1389) 1389
Russian (717) 717
Spanish (440) 440
Italian (375) 375
Japanese (250) 250
Polish (202) 202
Chinese (157) 157
Dutch (63) 63
Danish (62) 62
Hungarian (56) 56
Portuguese (54) 54
Romanian (54) 54
Czech (53) 53
Bulgarian (39) 39
Swedish (39) 39
Norwegian (32) 32
Ukrainian (27) 27
Finnish (26) 26
Croatian (22) 22
Slovak (20) 20
Hebrew (18) 18
Serbian (17) 17
Turkish (17) 17
Korean (6) 6
Afrikaans (5) 5
Lithuanian (5) 5
Bosnian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Drug Discovery Technologies, ISSN 1570-1638, 12/2009, Volume 6, Issue 4, pp. 281 - 289
Journal Article
2012, Handbook of experimental pharmacology, ISBN 9783642230561, Volume 207.
Web Resource
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
2012, Biochemistry research trends, ISBN 1621004317
Web Resource
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Circulation, ISSN 0009-7322, 04/2011, Volume 123, Issue 16, pp. 1745 - 1756
Background-Concerns persist regarding the risk of stent thrombosis in the setting of primary percutaneous coronary intervention for ST-segment elevation... 
stents | thrombosis | myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIALS | BARE-METAL STENTS | ROUTINE CLINICAL-PRACTICE | UNCOATED STENTS | CLOPIDOGREL | IMPLANTATION | LARGE 2-INSTITUTIONAL COHORT | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | DRUG-ELUTING STENTS | Recombinant Proteins - therapeutic use | Predictive Value of Tests | Myocardial Infarction - epidemiology | Coronary Thrombosis - epidemiology | Ticlopidine - therapeutic use | Hirudins | Humans | Metals | Middle Aged | Heparin - therapeutic use | Male | Angioplasty, Balloon, Coronary - statistics & numerical data | Drug-Eluting Stents - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Myocardial Infarction - therapy | Coronary Thrombosis - prevention & control | Drug-Eluting Stents - statistics & numerical data | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Antithrombins - therapeutic use | Risk Factors | Anticoagulants - therapeutic use | Coronary Restenosis - prevention & control | Treatment Outcome | Paclitaxel - therapeutic use | Ticlopidine - analogs & derivatives | Tubulin Modulators - therapeutic use | Coronary Restenosis - epidemiology | Aged | Peptide Fragments - therapeutic use | Complications and side effects | Care and treatment | Angioplasty | Research | Thrombosis | Heart attack | Stent (Surgery) | Blood clot | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Critical Care Medicine, ISSN 0090-3493, 01/2008, Volume 36, Issue 1, pp. 296 - 327
OBJECTIVE:To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, “Surviving Sepsis Campaign Guidelines for Management... 
Infection | Sepsis syndrome | Surviving Sepsis Campaign | Severe sepsis | Grades of Recommendation, Assessment, Development and Evaluation criteria | Sepsis bundles | GRADE | Sepsis | Septic shock | Evidence-based medicine | Guidelines | sepsis bundles | septic shock | infection | Grades of Recommendation | severe sepsis | DEEP-VEIN THROMBOSIS | ACUTE LUNG INJURY | ACUTE-RENAL-FAILURE | Assessment Development and Evaluation criteria | MEAN AIRWAY PRESSURE | RESPIRATORY-DISTRESS-SYNDROME | MECHANICALLY VENTILATED PATIENTS | CONTROLLED CLINICAL-TRIAL | INTENSIVE-CARE-UNIT | MOLECULAR-WEIGHT HEPARIN | guidelines | sepsis syndrome | CRITICALLY-ILL PATIENTS | sepsis | evidence-based medicine | CRITICAL CARE MEDICINE | Conscious Sedation - methods | Critical Care - methods | Recombinant Proteins - therapeutic use | Critical Care - standards | Analgesia - methods | Bicarbonates - therapeutic use | Humans | Renal Replacement Therapy - methods | Peptic Ulcer - prevention & control | Sepsis - diagnosis | Sepsis - complications | Drug Monitoring - methods | Shock, Septic - diagnosis | Adrenal Cortex Hormones - therapeutic use | Shock, Septic - therapy | Respiratory Distress Syndrome, Adult - etiology | Cardiotonic Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Delphi Technique | Fluid Therapy - methods | Shock, Septic - blood | Adult | Venous Thrombosis - prevention & control | Drug Therapy, Combination | Child | Blood Transfusion - methods | Respiratory Distress Syndrome, Adult - therapy | Vasoconstrictor Agents - therapeutic use | Resuscitation - methods | Neuromuscular Blockade - methods | Shock, Septic - complications | Venous Thrombosis - etiology | Sepsis - therapy | Sepsis - blood | Blood Glucose - metabolism | Peptic Ulcer - etiology | Protein C - therapeutic use | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus
Journal Article